A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes
暂无分享,去创建一个
M. Tormo | M. Voso | J. Cavenagh | G. Garcia-Manero | W. Copeland | A. Zeidan | S. Rose | L. Silverman | I. Boss | A. Hellmann | B. Fox | C. Beach | Ethan G. Thompson | Vanessa E Hasle | T. O'Connor | K. Ogasawara | A. Previtali | C.L. Beach